Investor Presentaiton
Across All Segments of T2D, CGM Use Increases with GLP-1 Initiation
% CGM usage for those initiating GLP-1 therapy
in each year
Type 2
Intensive Insulin
Average CGM Increase: 2.0x
CLINICAL DRIVERS OF CGM
USE WITH GLP-1
Provides insights and behavior
modification required for long-term
metabolic health
40.0%
30.0%
20.0%
10.0%
0.0%
2018
2019
20.0%
15.0%
10.0%
5.0%
0.0%
2018
2019
6.0%
4.0%
2.0%
0.0%
2018
2019
Dexcom
2020
2021
Type 2 Basal Insulin Only
Average CGM Increase: 3.8x
2020
2022
Supports dose titration for therapeutic
regimen, as recommended in GLP-1
labeling
Helps enable durability of health
outcomes
2021
2022
Type 2 Non-Insulin Therapy
Average CGM Increase: 4.2x
% Users on CGM prior to
initiating GLP-1
2020
2021
2022
% Users on CGM after
initiating GLP-1
Source: Optum Payer Claims Database, includes commercial and Medicare Advantage members.
Increasing access and simplicity of
CGM systems supports continued
acceleration of CGM adoption across all
T2D segments, including with GLP-1 use
23View entire presentation